Plasma Resilience: Europe's Lifeline
Human plasma, a protein-rich liquid making up 55% of our blood, is crucial for developing therapies for various conditions, including rare inherited disorders and immunodeficiencies.
Despite its importance, Europe's plasma supply chain is vulnerable, relying on the generosity of human donors, with over 12 million people donating plasma annually.
- Donations are governed by EU Member States' safety standards.
- International safety standards, such as the International Quality Plasma Program (IQPP), are also in place.
- Strict oversight is provided by the Plasma Protein Therapeutics Association (PPTA).
However, nearly 40% of plasma used to make medicines for Europe is imported from the United States, highlighting the need to strengthen the continent's plasma resilience.
Plasma is singularly human, and therapies made from it exist only thanks to the generosity of real people.
Author's summary: Europe's plasma supply chain is vulnerable and needs strengthening.
More News
- Events this weekend (Oct. 17–19)
- Knicks’ harsh Mitchell Robinson reality could open the door for a surprise breakout
- Party is on verge of ‘a historic breakthrough’ says Scottish Lib Dem leader
- Armenian Ambassador Lauds Ethiopia's Transformative Economic Reform, Corridor Dev’t
- Adams, Ejuke Fail To Help Sevilla Close Gap On Madrid After Defeat To Mallorca
- Oklahoma student says staff 'threat' after Charlie Kirk tribute won't silence him - FOX 24 WTAT
- Texas faces heightened wildfire threat amid ongoing drought
- Columbia Blacktails Are the Toughest Deer to Hunt
- Trump commutes George Santos' prison sentence out of pity: "Horribly mistreated!"